Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells

Biochemical Pharmacology

Volumn 74, Issue 2, 2007, Pages 191-201

  Duyndam, Monique C A ^a   van Berkel, Maria P A ^a   Dorsman, Josephine C ^a,b   Rockx, Davy A P ^a   Pinedo, Herbert M ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre for Medical Systems Biology   (Netherlands)

Author keywords

Cisplatin; Doxorubicin; HIF 1; P53; Taxanes; VEGF

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLOHEXIMIDE; DOCETAXEL; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; MESSENGER RNA; PACLITAXEL; PROTEIN P300; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; CARRIER PROTEINS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OVARIAN NEOPLASMS; P300-CBP TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249981734     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.003     Document Type: Article

References (38)

1. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76 (1997) 1221-1227
2. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 (2001) 853-865
3. Duyndam M.C., Hilhorst M.C., Schluper H.M., Verheul H.M., van Diest P.J., Kraal G., et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 160 (2002) 537-548
4. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
5. Nakayama K., Kanzaki A., Hata K., Katabuchi H., Okamura H., Miyazaki K., et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 176 (2002) 215-223
6. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338 (2005) 610-616
7. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
8. Freedman S.J., Sun Z.Y., Poy F., Kung A.L., Livingston D.M., Wagner G., et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 99 (2002) 5367-5372
9. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
10. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
11. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
12. Yeo E.J., Chun Y.S., and Park J.W. New anticancer strategies targeting HIF-1. Biochem Pharmacol 68 (2004) 1061-1069
13. Ferrara N., Hillan K.J., Novotny W., and Bevacizumab. (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 (2005) 328-335
14. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23 (1996) 40-47
15. Vasey P.A., Atkinson R., Coleman R., Crawford M., Cruickshank M., Eggleton P., et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 84 (2001) 170-178
16. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
17. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 (2005) 264-273
18. Kolfschoten G.M., Hulscher T.M., Duyndam M.C., Pinedo H.M., and Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 63 4 (2002) 733-743
19. Kolfschoten G.M., Hulscher T.M., Schrier S.M., van Houten V.M., Pinedo H.M., and Boven E. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol Oncol 84 (2002) 404-412
20. Yaginuma Y., and Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52 (1992) 4196-4199
21. Duyndam M.C., Hulscher T.M., Fontijn D., Pinedo H.M., and Boven E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J Biol Chem 276 (2001) 48066-48076
22. Wellmann S., Taube T., Paal K., Graf V.E.H., Geilen W., Seifert G., et al. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem 47 (2001) 654-660
23. Kaluzova M., Kaluz S., Lerman M.I., and Stanbridge E.J. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 24 (2004) 5757-5766
24. Duyndam M.C., Hulscher S.T., van der Wall E., Pinedo H.M., and Boven E. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. J Biol Chem 278 (2003) 6885-6895
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
26. Cong S.Y., Pepers B.A., Evert B.O., Rubinsztein D.C., Roos R.A., van Ommen G.J., et al. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 30 (2005) 560-571
27. Masson N., and Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 116 (2003) 3041-3049
28. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2, (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21 (2001) 3995-4004
29. Tee A.R., and Proud C.G. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19 (2000) 3021-3031
30. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
31. Schmid T., Zhou J., and Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 8 (2004) 423-431
32. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93 (1996) 12969-12973
33. Ruas J.L., Poellinger L., and Pereira T. Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 118 (2005) 301-311
34. Poizat C., Puri P.L., Bai Y., and Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol Cell Biol 25 (2005) 2673-2687
35. Hirota K., and Semenza G.L. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276 (2001) 21166-21172
36. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V., and Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278 (2003) 14013-14019
37. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
38. Escuin D., Kline E.R., and Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65 (2005) 9021-9028